Northern Biologics

8 articles about Northern Biologics

• Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio

  5/14/2020

  Acquisition provides assets targeting the tumor stroma and myeloid cells These new programs targeting the tumor microenvironment are the latest in a series of strategic acquisitions and collaborations that strengthen Boehringer Ingelheim’s position in cancer immunology, with leading assets and robust capabilities in cancer vaccines, oncolytic viruses, T-cell engagers and myeloid cell modulators Acquisition of Versant-built company based i

• Northern Biologics Reports Phase I Data Update for MSC-1, an Anti-LIF Antibody, at ESMO

  9/27/2019

  Northern Biologics Inc. announced the presentation of updated Phase 1a trial results of its lead antibody, MSC-1, at the European Society for Medical Oncology Congress in Barcelona, Spain.

• Northern Biologics Reports Initial Phase I Data for MSC-1 at AACR

  3/29/2019

  Northern Biologics Inc., a company focused on developing first-in-class immuno-oncology products, today announced the presentation of initial results from the Phase I trial of their lead antibody, MSC-1, at the American Association for Cancer Research meeting in Atlanta, Georgia.

• Applied BioMath, LLC Extends Collaboration into Phase 1 with Northern Biologics for Clinical Pharmacology Support and Semi-Mechanistic PK/PD Modeling Support in Oncology

  8/6/2018

  Applied BioMath announced an extension to their collaboration with Northern Biologics Inc. to include Phase I clinical analyses for MSC-1, their lead antibody therapeutic targeting the cytokine LIF for the treatment of cancer.

• Northern Biologics Strengthens Management Team

  8/1/2018

  Enda Moran appointed vice president, CMC, and Frédéric Sweeney joins as chief business officer

• Northern Biologics’ MSC-1 Enters the Clinic

  5/31/2018

  Northern Biologics Inc. announced that its lead immuno-oncology antibody, MSC-1, began clinical testing at Memorial Sloan Kettering Cancer Center with plans to soon expand to other world-leading sites in Canada and Europe.

• Northern Biologics Announces CEO Transition

  11/9/2017

  Philip Vickers, Ph.D., is joining the company as CEO and a member of the board.

• Celgene Dealmaking Continues With Two Pacts Worth $110 Million With Agios, Northern Biologics

  4/30/2015